Allergan has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator from partner Aptinyx. Aptinyx discovered AGN-241751 using its chemistry platform and the compound was selected for further development by Allergan under the companies’ ongoing research collaboration. Allergan was granted option rights to a limited number of small molecules from the Aptinyx discovery platform in conjunction with its 2015 acquisition of N...